Article

How Much MS Disease Activity Should Patients and Neurologists Tolerate?


 

References

“In our clinic, we’re now trying to actually improve patient function over time,” noted Dr. Vollmer. “We expect them to get better, particularly if they exercise and take some of the more highly effective therapies. Particularly for patients with the earlier phase disease, we’re looking for full disease remission, including remission of fatigue and depression symptoms.”

Functional recovery has become possible for some patients following the introduction of disease-modifying therapies with increased efficacy. Oral formulations of fingolimod, dimethyl fumarate, and teriflunomide also could become highly effective treatment options in the coming years. As these and other new drugs emerge, they could expand the number of patients who can achieve remission or improvement—and also make the suppression of MS disease activity increasingly feasible.


—Erik Greb
Senior Associate Editor

Pages

Recommended Reading

Preventing Disability Progression and MRI Changes May Be Top Goals for Patients With MS
ICYMI Multiple Sclerosis
Intermediate Levels of Vitamin A May Protect Against MS
ICYMI Multiple Sclerosis
Cognitive Reserve May Protect Against MS-Related Cognitive Decline
ICYMI Multiple Sclerosis
Smoking May Increase Young People's Risk of MS
ICYMI Multiple Sclerosis
Ethnicity May Influence Risk of JCV in Patients With MS
ICYMI Multiple Sclerosis
Early Relapses May Not Correlate With the Onset of Secondary MS
ICYMI Multiple Sclerosis
Are Ethnicity and Duration of Natalizumab Exposure Risk Factors for JCV Infection?
ICYMI Multiple Sclerosis
Disputing the Zamboni Effect in MS
ICYMI Multiple Sclerosis
New and Noteworthy Information—January
ICYMI Multiple Sclerosis
When Should a Patient With MS Switch Therapies?
ICYMI Multiple Sclerosis